A comprehensive view of Non-Vaccine Biologics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Lotte Biologics to invest US$3.0B by 2030 to build three mega plants in South Korea with total capacity of 360,000 liters of antibody drugs; commercial production to start in 2027 and all three plants to be fully operational by 2034

Pfizer Listed a New Clinical Trial to Understand Long-term Safety and Effects of Fordadistrogene Movaparvovec Experimental Gene Therapy for Duchenne Muscular Dystrophy

Merck wraps up US$1.35B deal for US-based Imago Biosciences; Imago to become wholly-owned subsidiary of Merck

Autobahn Therapeutics announces initiation of a Phase 1 clinical trial of ABX-002 for the treatment for major depressive disorder; ABX-002 is a selective brain-boosting thyroid receptor beta agonist

Pfizer, partnering with Sosei Group, announces dosing of first subject in Phase 2 clinical trial of PF-07081532, a candidate for treatment of type 2 diabetes and obesity; trial marks a development milestone, triggering US$10M payment to Sosei

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count